Biotech Growth Trust plc (The) (BIOG) Ordinary 25p

- Add to watchlist
- Create an alert
- This stock can be held in a




1,538.00p
1,576.00p
1,750.00p
1,571.28
1,550.00p
1,460.00p
680.00p
-3.14%
28.00p (1.84%) Previous:
28.00p
150,203
n/a
GBX
Price
-
Net Asset Value (NAV)

Performance
1 week 1W | 2.51% | 1 year 1Y | 65.6% |
---|---|---|---|
1 month 1M | 1.52% | 2 years 2Y | 114.09% |
3 months 3M | 3.2% | 3 years 3Y | 108.61% |
6 months 6M | 28.1% | 5 years 5Y | 150.4% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Trust Basics
Benchmark: | NASDAQ Biotechnology TR GBP |
---|---|
Annual management charge: | 0.65% of Net Assets |
Performance fee: | Yes |
Ongoing charge: | 1.10% |
Dividend yield: | n/a |
Dividend frequency: | Annually |
Total assets: | £659m |
Gross gearing: | 101% |
Market capitalisation:Market cap.: | £631m |
Shares in issue: | 41.39 million |
Legal structure | Closed Ended Investment Company |
Domicile: | United Kingdom |
ISIN | GB0000385517 |
Dividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
To buy shares in , you'll need to have an account. Try our handy filter to explore the different options.
Ready to take your first step?
To invest in , you'll need to open an account.
Try our handy filter to find which one suits you best.
Important Documents
Objective
NET ASSET VALUE (NAV)
Estimated NAV: | 1,571.28 |
---|---|
Latest actual NAV: | 1,579.55 |
Latest actual NAV date: | 1 March 2021 |
Premium/Discount: | -3.14% |
12m average Premium/Discount: | -2.33% |
NAV frequency: | Daily |
Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.
Security | Weight |
---|---|
Alexion Pharmaceuticals Inc | 4.93% |
Horizon Therapeutics plc Ordinary Shares | 3.96% |
Neurocrine Biosciences Inc | 3.85% |
Turning Point Therapeutics Inc | 3.76% |
Keros Therapeutics Inc | 3.69% |
Burning Rock Biotech Ltd ADR | 2.95% |
Arcturus Therapeutics Holdings Inc | 2.83% |
Vertex Pharmaceuticals Inc | 2.80% |
Mirati Therapeutics Inc | 2.48% |
Trillium Therapeutics Inc | 2.48% |
Sector | Weight |
---|---|
Healthcare | 97.97% |
Country | Weight |
---|---|
United States | 72.31% |
Canada | 10.42% |
China | 9.59% |
United Kingdom | 2.24% |
Switzerland | 2.21% |
Cayman Islands | 1.11% |
Denmark | 0.52% |
Ireland | 0.40% |
Germany | 0.27% |
Key Dates
Launch date: | 23 June 1997 |
---|---|
Financial year end: | March |
Next AGM: | July 2021 |

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.